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Summary 
High doses of aqueous protein antigens induce a form of immunological tolerance in which 
interleukin 2 (Ib2)- and interferon 3' (IFN-T)-secreting T helper type 1 (Thl) cells are inhibited, 
but IL-4-secreting  (Th2) cells are not. This is manifested by reduced proliferation of antigen- 
specific T cells upon in vitro restimulation, and marked suppression of specific antibody responses 
of the immunoglobulin (Ig)G2a, IgG2b, and IgG3 isotypes, but not of IgG1 and IgE. The role 
of the immunomodulatory cytokine I1-4 in this model of unresponsiveness to protein antigens 
has been examined. Administration of tolerizing antigen itself primes splenic CD4 + T cells for 
secretion of lymphokines, both I1.2 and I1-4. Neutralization of I1-4 in vivo with the anti-I1-4 
antibody 11Bll during tolerance induction augments IFN-y production by T cells of tolerant 
mice, and reverses the suppression of IgG2a, IgG2b, and IgG3. This blockade of I1.4 function 
does not, however, restore the proliferative responses of T cells, suggesting that reduced T cell 
proliferation is due to direct T cell inactivation or anergy. Inhibiting the activity of IL-4 in vivo 
also inhibits the expansion of antigen-specific Th2-1ike cells, which are resistant to the induction 
of unresponsiveness.  Thus, the immunologic consequences of high-dose tolerance are due to a 
combination of clonal T  cell anergy and I1.4-mediated immune regulation. 
T 
he induction of peripheral T cell tolerance to specific an- 
tigens is a well-known phenomenon (for reviews, see 
references 1-3). Tolerance in an individual may be due to sev- 
eral mechanisms, including deletion or anergy of antigen- 
specific lymphocytes and suppression by other cells or factors, 
all of which have been implicated in tolerance to self and for- 
eign antigens. In vitro studies have shown that cloned lines 
of CD4 + T lymphocytes can be rendered anergic by antigen 
stimulation in the absence of costimulatory signals (4). This 
form of anergy is associated with a block in I1.-2 gene tran- 
scription, and, as a result, a reduction in proliferative responses. 
Anergy is readily induced in I1.2- and IFN-3,-secreting  (Thl- 
type) helper clones, but not in I1.4-, I1.5-, and IL-10-secreting 
(Th2-type) clones  (5,  6). 
Recently, inhibition of specific and nonspecific immune 
responses has been recognized as a regulatory action of many 
cytokines. For instance, I1.4 and IFN-3' reciprocally antagonize 
the actions of each other on B cells (7),  and each inhibits 
the differentiation of naive T cells into secretors of the other 
cytokine (8-10). TGF-~ also antagonizes the development of 
I1.4-secreting T cells (11). I1.10 suppresses the activation of 
T cells, notably Thl cells, by inhibiting the function of mac- 
rophages as APC (12, 13). Thus, in many experimental systems, 
cytokines serve as potent downmodulators of lymphocyte 
differentiation and activation, with I1.4 exerting an inhibi- 
tory effect on Thl-like responses, and IFN-3' doing the same 
to Th2-1ike responses. Selective expression of cytokines is also 
known to be important in the hyporesponsive state associated 
with many chronic microbial diseases, particularly leprosy 
(14) and various parasitic infections (15). In these diseases, 
I1.4 and I1.10 expression are associated with suppressed cell- 
mediated immunity, whereas IFN-3' expression is found in 
more reactive lesions. 
These observations raise the possibility that cytokine regu- 
lation plays a role in antigen-specific  tolerance in vivo. Such 
a possibility has not been formally explored to date. Several 
regimens for inducing tolerance to foreign antigens in vivo 
have been described,  including the administration of large 
quantities of aqueous antigens (high-dose tolerance), providing 
antigens in ways that selectively target costimulator-deficient 
APC, and antigen feeding (oral  tolerance).  Previously,  we 
and others have shown that in a model of high-dose toler- 
ance, parenteral administration of soluble protein antigens 
to adult mice induces unresponsiveness in Thl- but not Th2- 
type lymphocytes (16, 17). In this model, immunization and 
in vitro restimulation show that antigen-specific T cell prolifer- 
ation and production of I1-2 and IFN-y are inhibited, but 
secretion of IL-4 is unaffected, The antigen-specific antibody 
repertoire shows changes consistent with a selective inhibi- 
tion of Thl cells. Serum levels of antigen-specific IgM, IgG1, 
and IgE, isotypes unaffected or sustained by I1.4, are normal 
or even increased, while specific IgG2a, IgG2b, and IgG3, 
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(7, 18, 19), are greatly reduced. Direct tolerization of antigen- 
specific B cells does  not occur in this system. 
We have now explored the contribution of IL-4 to the es- 
tablishment of high-dose tolerance, and its effect on lympho- 
kine-producing T cells in tolerized animals. An IL-4 antagonist 
augments antibody responses in tolerant animals and increases 
IFN-3' production by T cells, but does not prevent the block 
in the IL-2-dependent  proliferation of antigen-specific  Thl- 
like cells. In addition, neutralization of IL-4 during tolerance 
induction reveals that IL-4 serves as a growth and differentia- 
tion factor for Th2 cells in vivo, and accounts for their ex- 
pansion in tolerized animals.  Thus, high-dose tolerance in 
vivo may be due to a combination of clonal anergy of Thl 
cells and inhibition mediated by Th2-derived cytokines. 
Materials and Methods 
Antigens,  Cytokines, and Antibodies.  TNP-conjugates of OVA, 
BSA, and rabbit gamma globulin (Sigma Chemical Co., St. Louis, 
MO) were prepared as described previously (19). Purified protein 
derivative (PPD)  1 of Mycobacterium tuberculosis was kindly donated 
by Lederle  Biologicals  (Pearl River, NY). Murine II.-4 was gener- 
ously provided by Dr. Steve Gillis (Immunex Corp., Seattle, WA); 
murine IL-2 was from Genzyme (Boston, MA). HPLC-purified 
11Bll, the neutralizing mAb for IL-4 (20), was kindly provided 
by Dr. Craig Reynolds (Biological Response Modifiers Program, 
National Cancer Institute, Frederick, MD). The neutralizing mAb 
for IL-2, $4B6 (21), was a gift from Dr. Tim Mosmann (University 
of Alberta, Edmonton,  Canada). 
Induction of High-Dose  Tolerance and I1B11 Treatments.  Female 
CAFI mice (BALB/cJ x  A/J)F1 (The Jackson Laboratory, Bar 
Harbor, ME), aged  6-8 wk, were used for all experiments. Animals 
were maintained in accordance with the guidelines of the Com- 
mittee on Animals of Harvard Medical School and those prepared 
by the Committee of Care and Use of Laboratory Animals of the 
Institute  of Laboratory Animal  Resources, National  Research 
Council. To induce tolerance, animals  were given  the indicated  quan- 
tity of TNP-OVA in PBS intraperitoneaUy,  or the equivalent  volume 
of PBS, on days 1, 3, and 5 of the experiment. On day 8, animals 
were immunized in the footpad with ~100 #g TNP-OVA in CFA 
(IFA and fixed M.  tuberculosis; Difco Laboratories, Detroit,  MI). 
On day 17, mice were bled for serum and killed, and draining lymph 
nodes were collected. In experiments analyzing splenic responses, 
spleens were harvested on experiment day 8 before immunization 
of the mice. 
For anti-IL-4 mAb treatments, animals were given 2 mg of 
HPLC-purified 11Bll in PBS on days 0 and 4 of the experiment, 
and 1 mg on day 8.  Control animals were given an equivalent 
volume of PBS. This dose of 11Bll has been shown to block 
99% of the IL-4  dependent, nematode-induced  primary IgE response 
in mice (22). 
Cell Preparation, Cultures, and Lymphokine  Bioassays.  Lympho- 
cyte suspensions from draining lymph nodes or spleen were pre- 
pared by grinding tissue through sterile wire mesh; for lymph node 
cells, lymphocytes from two mice in each treatment group were 
pooled. CD4 § cells were depleted from splenocytes using two 
rounds of anti-CD4 antibodies, GK1.5 (23) and RL172 (24), and 
guinea pig complement (Cedarlane Laboratories, Hamilton, On- 
1 Abbreviation used in this paper: PPD, purified protein derivative. 
tario,  Canada). This  procedure  effectively depleted >98%  of 
CD4 § cells. For proliferation assays, 4  ￿  105 cells were cultured 
in 0.2 ml RMPI 1640 supplemented with 2 mM r-glutamine, pen- 
icillin, streptomycin, nonessential amino acids, sodium pyruvate, 
10 mM Hepes (all from Gibco Laboratories, Grand Island, NY), 
5  x  10 -5 M 2-ME, and  10%  heat-inactivated FCS (HyClone 
Laboratories, Logan,  UT),  at  37~  in  96-well flat-bottomed 
microculture plates in 5% CO2. OVA or PPD was added as indi- 
cated in the figures; proliferation was measured on day 3 of  culture 
by [3HITdR incorporation.  For lymphokine production  assays, 
6  x  105 lymph node cells or 8  ￿  105 spleen cells were cultured 
in medium alone or medium with antigen as indicated, and super- 
natants were collected at 48 or 72 h. IL-2 levels were measured by 
using the IL-2/IL-4-sensitive  indicator line HT-2 in the presence 
of the blocking antibody 11Bll (10 #g/ml) as described (16). I1_,4 
levels were determined  using the II~4-dependent  indicator  line CT.4S 
(25; kindly provided by Drs. R. Seder and W. E. Paul, National 
Institutes of  Health) in the presence of the anti-IL-2  antibody $4B6 
(1:1,000 dilution of ascites) to assure specificity.  In this assay, half- 
maximal stimulation of CT4S cells is seen with 10-20 U/ml of 
rlL-4, the units having been originally defined by the suppliers on 
the basis of B cell costimulation assays. IFN-3, activity was mea- 
sured by inhibition of proliferation of the B lymphoma line WEHI 
279 as described (16). Concentrations in units/milliliter were de- 
termined using purified recombinant cytokines as standards, and 
were based on concentrations provided by the suppliers. Standard 
deviations were all <10%  of sample values. 
Assays for Anti-TNP Antibodies.  Serial  dilutions ofsera were ana- 
lyzed for TNP-specific antibodies by ELISA. Titers of anti-TNP 
IgM, IgG1, IgG2a, IgG2b, and IgG3 isotypes were determined 
using plates coated with TNP-BSA, and isotype-specific  alkaline 
phosphatase-conjugated  developing  reagents as described  previously 
(19). TNP-specific IgE was measured using a pan-IgE capture re- 
agent, followed  by a sandwich  ELISA  of serum, TNP-rabbit gamma 
globulin, and anti-rabbit Ig reagents as described previously (16). 
Results and Discussion 
Tolerogenic Antigen Stimulates Lymphokine-producing  T  Cells. 
If IL-4 plays a role in the induction or maintenance of high- 
dose tolerance,  then tolerogenic antigens should themselves 
stimulate IL-4 production. To test this, aqueous TNP-OVA 
was injected into mice intraperitoneally at doses previously 
shown to induce tolerance (16). Splenocytes were isolated and 
examined for lymphokine production upon restimulation with 
OVA in culture. As shown in Table 1, at high cell numbers 
splenocytes from TNP-OVA-pretreated  mice secreted low but 
detectable,  antigen-inducible levels of IL-4 and II.-2 upon res- 
timulation with OVA. Proliferative responses  of these cells 
were minimal (not shown), and mice given aqueous TNP- 
OVA did not contain detectable anti-TNP IgG1 or IgG2a an- 
tibodies in their sera (16). 
It has recently been demonstrated that an important source 
of IL-4 is a non-B, non-T population of cells that belong to 
the mast cell/basophil lineage and release lymphokine in re- 
sponse to Fc receptor-mediated signaling (26, 27). It was pos- 
sible that aqueous antigens induced Igs capable of sensitizing 
Fc receptors  on these cells, facilitating Ib4 release on subse- 
quent exposure to antigen. Two approaches were used to es- 
tablish the cellular source of IL-4. First, depletion of CD4 + 
cells from splenocytes was found to completely abolish antigen- 
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TNP-BSA was shown to be incapable of stimulating IIA secre- 
tion by splenocytes from TNP-OVA-pretreated mice (Table 
1). These results indicate that crosslinking bound anti-TNP 
Ig on inflammatory cells is not the mechanism of IL-4 re- 
lease, and that lymphokine production is carrier specific,  as 
expected of a T cell response. Thus, even tolerogenic aqueous 
protein antigens at high doses are capable of "priming" splenic 
11.-2- and IL-4-producing CD4 §  T  cells. 
Anti-IL,4 Antibody Enhances Specific Antibody Production in 
Tolerized Mice but Does Not Prevent the Block in T Cell Prolifer- 
ation.  The above results raised the possibility that high-dose 
tolerance may, at least in part, be due to the effects of IL-4, 
which is stimulated by tolerogenic antigen.  Were this the 
case, specifically antagonizing the effects of IL-4 ought to re- 
duce or prevent tolerance. To test this, mice were treated with 
aqueous TNP-OVA at tolerogenic doses on days  1, 3,  and 
5 of the experiment, given 2 mg of the anti-Ib4 mAb 11Bll 
on days 0 and 4 and 1 mg on day 8, and were immunized 
with antigen in adjuvant on day 8.  Serum antibody levels 
and T cell responses to in vitro restimulation were determined 
9 d later. Titers of serum anti-TNP antibody of different iso- 
types are shown in Fig. 1. As previously reported (16), pretreat- 
ment  with  tolerogenic antigen  markedly  suppressed  the 
production of IgG2a, IgG2b, and IgG3, all of which are in- 
hibitable by IIr4 (18, 19), but did not inhibit IgG1 and IgE, 
which are enhanced by or dependent on IL-4 (Fig.  1,  left). 
When tolerance was induced in a parallel set of mice treated 
with 11Bll, the production of IgG2a, IgG2b, and IgG3 was 
greatly increased (Fig.  1, right). Mice given the lower tolero- 
genic doses and 11Bll had titers two- to fivefold higher for 
these isotypes than even control mice that were immunized 
without prior administration Of tolerogen. At the highest 
dose of tolerogen, the  11B11-treated  mice showed reduced 
production  of  these  isotypes  compared  with  mice  not 
pretreated with tolerogenic antigen. This is probably due to 
the induction of anergy in T cells, which results in reduced 
expansion of helper T cells in vivo. Anti-IL-4 antibody treat- 
ment abolished specific IgE production, demonstrating that 
IL-4 was effectively  neutralized by 11Bll in vivo. 11Bll treat- 
Table  1.  Splenocytes  from  Tolerogen-treated  Mice Secrete IL-2 and 11.-4 
Tolerogen  Dose  Cells  Medium 
Lymphokine  responses to restimulation  with: 
OVA  OVA  OVA  TNP-BSA 
(300/zg/ml)  (1,000/zg/ml)  (2,000/zg/ml)  (1,000/zg/ml) 
/~g 
IL-2 
PBS 
TNP-OVA  50 
TNP-OVA  200 
TNP-OVA  1,000 
IL-4 
PBS 
TNP-OVA  SPL 
TNP-OVA  200 
TNP-OVA  1,000 
U/ml 
SPL  1.10  0.48  1.83  1.51  NT* 
CD4 dep.  <0.2  <0.2  <0.2  <0.2  NT 
SPL  0.40  2.44  3.52  6.16  NT 
CD4 dep.  <0.2  <0.2  <0.2  <0.2  NT 
SPL  2.11  3.04  3.79  4.07  NT 
CD4 dep.  <0.2  <0.2  <0.2  <0.2  NT 
SPL  1.25  0.86  3.06  4.30  NT 
CD4 dep.  <0.2  <0.2  <0.2  <0.2  NT 
SPL  0.14  0.14  0.20  0.17  <0.1 
CD4 dep.  <0.1  <0.1  <0.1  <0.1  <0.1 
50  <0.1  0.22  0.73  0.57  <0.1 
CD4 dep.  <0.1  <0.1  <0.1  <0.1  <0.1 
SPL  0.14  0.25  0.56  0.96  0.12 
CD4 dep.  <0.1  <0.1  <0.1  <0.1  <0.1 
SPL  <0.1  0.20  0.40  0.58  0.12 
CD4 dep.  <0.1  <0.1  <0.1  <0.1  <0.1 
Mice were pretreated with PBS or aqueous TNP-OVA at the indicated doses on days 1, 3, and 5. Splenocytes  were collected  on day 8, and cultured 
at 8  x  10  s per well in medium alone, or with antigen at the indicated concentrations (/zg/ml). CD4+ T cells were depleted from splenocytes  by 
treatment with anti-CD4 antibodies and complement, and also cultured at 8 x  10  s per wall (CD4 dep.). Lymphokine  levels  were determined  from 
supernatants taken from cultures on day 2 (IL-2) or day 3 (IL-4). Data are means of concentrations  of lymphokines from two mice per group. SE 
were <10% of sample values in all cases. Results are from one representative  experiment out of three. 
" NT, not tested. 
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Figure  1.  Effects  of 11.1311 treatment  during  tolerance  induction on 
antigen-specific antibody isotypes. Mice were treated  with PBS (11) or 
rendered tolerant  with aqueous TNP-OVA (l-q,  three  50-#g doses;  O, 
three 200-#g doses; O, three 1,000-#g doses) before subcutaneous  immu- 
nization with TNP-OVA in CFA. In each group, half the animals  were 
given 11Bll during tolerance induction (right)  and the other half PBS (left). 
Sera from immunized mice were analyzed for TNP-specific lg by ELISA. 
The ordinate  axes are fold dilutions of serum;  antibody titers  are means 
from two mice,  shown as OD40s.  Error bars are SD. 
ment also had a modest  effect on IgG1 production  in the 
tolerized mice, consistent with the demonstration that IL-4 
potentiates but is not required for switching to IgG1 (28). 
In summary, the levels of antibodies that are reduced in toler- 
ized mice were increased by neutralization of IL-4. 
The induction of tolerance is also characterized by reduced 
T cell proliferation (anergy) after immunization  and in vitro 
restimulation with antigen.  In such experimental systems, 
T cell proliferation induced by restimulation with antigen 
in vitro is directly proportional to the priming and clonal 
expansion of antigen-specific T cells as a result of immuniza- 
tion in vivo. As shown in Fig. 2 A, in mice pretreated with 
tolerogenic doses of aqueous TNP-OVA and immunized with 
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Figure  2.  llBll treatment does not prevent the block of T cell prolifer- 
ation induced by aqueous antigen. Mice were pretreated with PBS or aqueous 
TNP-OVA at the indicated doses, and immunized with TNP-OVA in CFA. 
Mice in B were also treated with 11Bll, while those in A received an equiva- 
lent volume of PBS.  Immune lymph node cells pooled from two mice 
per group were cultured at 4  x  10  s per well with either OVA or PPD 
as indicated.  Data are proliferation  on day 3 expressed  as cpm; error bars 
denote SD. 
TNP-OVA in CFA, the subsequent proliferation of T cells 
in response to restimulation with OVA was inhibited. Prolifer- 
ative responses to PPD, a component  of the adjuvant, were 
not affected, demonstrating the antigenic specificity of the 
T cell unresponsiveness. Treating mice with 11Bll at the time 
of the induction of unresponsiveness to soluble antigen did 
not prevent the subsequent block in T cell proliferation (Fig. 
2 B).  Thus,  the unresponsiveness of T  cells in this model 
is likely due to deletion or functional inactivation (anergy) 
of antigen-specific T cells in vivo, and is not caused by IL-4- 
mediated suppression. 
Anti-IL4 Antibody Alters the Profile of Lymphokine Produc- 
tion by T Cells in Tolerant  Animals.  The observation that anti- 
IL-4 antibody significantly reverses the suppression of some 
antibody isotypes  in tolerant animals may be explained by 
several potential actions of Ib4. This cytokine may be respon- 
sible for the expansion of Th2 cells, the inhibition of IFN-7 
production by viable Thl cells, and the negation of the effects 
of IFN-7 on isotype switching by B cells. We therefore ex- 
amined the profile of cytokines  produced by T  cells from 
animals that were pretreated with aqueous antigen with or 
without  11Bll  and then  immunized.  In accordance with 
previous results (16), T cells from tolerant mice (without 111111 
treatment) showed reduced Ib2 and IFN-7 secretion upon 
restimulation in vitro, but no suppression, and even a modest 
increase, in IL4 production.  In contrast, T ceils from mice 
given tolerogen and 11Bll produced markedly less II.-4 and 
more IFN-7 than those from animals treated with tolerogen 
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Lymphokine responses to restimulation  with: 
OVA  OVA  PPD 
Tolerogen  Dose  Medium  (300/~g/ml)  (1,000/~g/ml)  (30/zg/ml) 
~g  U/ml 
IL-2 without  11Bll  treatment 
PBS  <0.2  3.33  5.60  3.93 
TNP-OVA  50  <0.2  0.66  1.39  2.44 
TNP-OVA  200  <0.2  0.76  0.84  4.03 
TNP-OVA  1,000  <0.2  0.36  0.97  9.32 
IL-2 with  11Bll  treatment 
PBS  <0.2  3.76  7.76  2.99 
TNP-OVA  50  <0.2  0.88  1.46  8.76 
TNP-OVA  200  <0.2  0.27  0.99  7.32 
TNP-OVA  1,000  <0.2  <0.2  0.76  6.12 
IL-4 without  11Bll  treatment 
PBS  <0.1  (199)  <0.1  (723)  0.21  (2,491)  NT* 
TNP-OVA  50  <0.1  (591)  0.26  (3,273)  0.36  (5,559)  NT 
TNP-OVA  200  <0.1  (474)  0.25  (3,128)  0.48  (7,249)  NT 
TNP-OVA  1,000  <0.1  (696)  <0.1  (895)  0.18  (1,987)  NT 
IL-4 with  11Bll  treatment 
PBS  <0.1  (863)  0.23  (2,686)  0.20  (2,240)  NT 
TNP-OVA  50  <0.1  (854)  <0.1  (948)  0.11  (1,577)  NT 
TNP-OVA  200  <0.1  (26)  <0.1  (132)  <0.1  (577)  NT 
TNP-OVA  1,000  <0.1  (523)  <0.1  (723)  <0.1  (686)  NT 
IFN-3, without  11Bll  treatment 
PBS  0.58  8.98  27.64  33.33 
TNP-OVA  50  0.53  4.74  12.32  20.23 
TNP-OVA  200  0.59  3.25  6.47  20.56 
TNP-OVA  1,000  0.52  0.94  0.91  28.05 
IFN-~ with  11Bll  treatment 
PBS  0.32  9.32  30.49  33.57 
TNP-OVA  50  0.50  11.86  19.86  23.32 
TNP-OVA  1,000  0.30  6.59  12.98  31.05 
Mice were tolerized with TNP-OVA at the indicated doses and half were treated with 11Bli, before subcutaneous immunization with TNP-OVA 
in CFA.  Immune lymph node cells (6  x  105) were cultured with medium, OVA, or PPD at the concentrations indicated. Supematants from day 
2 cultures were analyzed for IL-2; supernatants taken on day 3 were analyzed for IL-4 and IFN-% Data are means of lymphokine concentrations. 
SE were <10% of sample values in all cases. For IL-4, the actual values of CT4S proliferation minus the background (Acpm) induced by culture 
supematants at 50% (vol/vol) are also shown. In this experiment, CT4S proliferation in medium (background) was 2,120  _+ 247 cpm; with 1 U/ml 
IL-4, 12,328 •  915 cpm; 12.5 U/ml IL-4, 41,015  _+ 2,996 cpm; and 25 U/m1 IL-4, 79,243 •  1,824 cpm. Groups showing significant effects of 
11Bll  are indicated in bold.  Results are from one representative experiment out of three. 
* NT, not tested. 
alone, but showed no change in IL-2 secretion (Table 2).  In 
three  experiments,  administration  of  tolerogenic  antigen 
(200-1,000 gg) reduced subsequent in vitro IL-2 production 
by immune T cells by an average of 86.5%, and reduced IFN-3, 
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production by 89.4%, compared with T  cells from immunized 
(and not tolerized) mice. In mice given tolerogen and 11Bll, 
II.-2 production  remained reduced by 91%,  whereas IFN-3' 
levels were restored to 43%  of controls.  In all three experi- ments,  I1-4 secretion by immune T  cells was almost com- 
pletely suppressed by prior administration  of llBll.  Thus, 
neutralizing  the effects  of I1-4 at the time of induction  of 
tolerance in Thl cells has two consequences on lymphokine- 
producing T ceils: it prevents the concomitant expansion of 
I1-4-secreting Th2 cells, and it enhances IFN- 7 production. 
Anti-I1-4 does not prevent the inhibition  of I1-2  secretion 
by T ceils from tolerized mice, suggesting that the block in 
I1-2  is a direct effect of the tolerogen,  presumably from a 
form of T cell anergy.  Surviving, anergized Thl-like cells are 
nonetheless secreting IFN-7,  reminiscent  of findings from 
in vitro experiments where T  cell anergy causes near com- 
plete inhibition of II-2 secretion and only partial inhibition 
of IFN-7  secretion (4). 
Based on the results described above, the following sequence 
of events in tolerance induced by high doses of aqueous an- 
tigens can be envisioned. Administration of aqueous antigen 
induces clonal anergy in tolerance-sensitive,  I1-2-producing 
cells of the Thl subset, a direct consequence of antigen rec- 
ognition. Tolerance in these cells may be due to antigen pre- 
sentation by APC such as resting  B cells  or macrophages, 
which lack necessary costimulators (29). Anergy of Thl cells 
is manifested by a block in clonal expansion in vivo, which 
is assayed by reduced I1-2 production and proliferation upon 
restimulation with antigen.  At the same time, aqueous an- 
tigen  stimulates  I1-4  production  by  CD4*  T  cells,  en- 
hancing the differentiation of Th2-1ike cells that are resistant 
to tolerization.  Subsequent immunization with antigen and 
adjuvant induces further expansion of Th2-1ike cells, which 
serve as a source of continuing  I1-4  production.  This  I1-4 
may mediate  several  of the  immunologic  changes  seen in 
tolerant mice. First, IL-4 drives the production of IgG1 and 
IgE, and inhibits the antigen-induced switching to and secre- 
tion of IgG2a,  IgG2b, and IgG3 isotypes. Second, Ib4 in- 
hibits IFN-'y production by any residual anergic Thl  cells 
that have retained the ability to secrete IFN-7. IL-4 has been 
shown to inhibit IFN-3' production by T  cells in vitro (30, 
31). Finally,  the Th2 cells that are expanded by I1-4 may se- 
crete other cytokines, such as I1-10, that further suppress Thl- 
dependent  responses  (12,  13). 
These findings indicate that there are multiple mechanisms 
of tolerance operating at the organismal and the cellular level. 
The phenomenon of tolerance in the intact animal,  as mea- 
sured by antibody responses, is attributable in part to the sup- 
pressive actions of I1-4, whereas the tolerogen-induced inhi- 
bition of Thl cells is a form of cellular unresponsiveness or 
anergy that is largely independent  of exogenous cytokines. 
The roles of cytokines in other models of tolerance remain 
to be explored. Identifying the mechanisms of tolerance has 
important implications for the design of therapeutic strategies 
to inhibit pathologic immune responses.  High-dose tolerance 
may be especially effective for disorders caused by Thl-mediated 
delayed-type hypersensitivity reactions.  Additionally, in high- 
dose tolerance, selective activation of Th2-type T  cells may 
account for skewing immune reactions towards hyporespon- 
sire states,  as has been found in chronic microbial infections 
with high antigenic loads. Antagonizing the cytokine activities 
augmented in such diseases may be one way of ameliorating 
these conditions. 
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